Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2Recurrence 1Ependymoma 1Disease Progression 1

Interventions

Bevacizumab 10Magnetic Resonance Spectroscopy 9Temozolomide 8Cyclophosphamide 8Etoposide 7X-Rays 6Phantoms, Imaging 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Cisplatin 5Radiotherapy 4Irinotecan 4Filgrastim 4Carboplatin 4Biopsy 4Erlotinib Hydrochloride 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2Vincristine 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ependymoma × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡